Lord's Mark Industries Limited has established a new state-of-the-art In Vitro Diagnostics (IVD) manufacturing facility admeasuring approximately 14,000 sq. ft. at Vasai (East), Maharashtra.
The facility, originally scheduled to commence operations in August 2026, has become operational two months ahead of schedule. With the commissioning of this facility, the Company's total operational manufacturing footprint has increased from 20,000 sq. ft. to 34,000 sq. ft.
The new manufacturing unit is designed to strengthen the Company's production capabilities and will manufacture a portfolio of 56 ELISA test kits along with a new range of rapid diagnostic test kits. The enhanced capacity is expected to improve operational efficiency, support increasing market demand, and strengthen the Company's position in the diagnostics sector.
The Company further informs that the Research & Development division of the facility has been dedicated to the memory of Late Shri Ratan Tata and will focus on indigenous molecular biology research and genetic science initiatives aimed at strengthening domestic scientific capabilities.
As part of its long-term growth strategy, the Company has also planned the establishment of a third facility at Vasai, Maharashtra, which will be dedicated to research for early cancer detection and named in honour of the Late Dr. A.P.J. Abdul Kalam. The proposed facility is expected to commence operations from January 2029. Further, the Company has outlined its vision to establish one of the world's largest medical device manufacturing facilities in India focused on Al-enabled and imagingbased diagnostic devices, reinforcing its commitment towards innovation, healthcare accessibility and global competitiveness.
Commenting on the development, Mr. Sachidanand Upadhyay, Managing Director of the Company, stated: "Every milestone we mark is guided by a simple conviction, that world-class healthcare must be built in India, for India and the world. Deeply inspired by the vision of the late Shri Ratan Tata, we are committing our research, our capacity and our purpose to outcomes that matter: indigenous science, earlier cancer detection, and devices that make quality diagnosis accessible to all. We have everything it takes to become the world's partner in wellness and we will."